-
UCB-bepranemab
UCB & Tubize krijgen een tik
Eerst vond ik enkel een mededeling dat ze op een symposium in Madrid meer nieuws zullen verstrekken. En terloops staat er ook bij dat ze alle rechten op bepranemab ‘teruggewonnen’ hebben van Genentech/Roche.
Maar dat is wel een deal met een potentieel 2mjd usd die ze vroeger al aangekondigd hadden die nu afgesprongen is.
Vandaar waarschijnlijk de dip. Ben eens benieuwd of de volgende dagen nog andere beleggers hun positie gaan herbekijken.
Wat volgt zijn quotes uit medelingen op ucb website :
Brussels, Belgium – 22 October 2024 – 7.00AM CEST
UCB today announced that the results of its double-blind TOGETHER (AH0003) Phase 2a study of bepranemab – an investigational anti-tau antibody – in people living with prodromal to mild Alzheimer’s Disease (AD), have been accepted for presentation in a late-breaking symposium at the 2024 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting.<sup>2</sup> The CTAD meeting will take place in Madrid, Spain, October 29 – November 1, 2024.
UCB also announced today that the company has regained all global rights to bepranemab following termination of a Collaboration Agreement with Genentech, a member of the Roche Group, and Roche. In July 2020, UCB entered a worldwide, exclusive license agreement with Roche and Genentech, for the global development, manufacturing, and commercialization of bepranemab in Alzheimer’s disease.<sup>3</sup>
<sup>
</sup>Brussels (Belgium) 29 July 2020<sup>
</sup>UCB0107 is an investigational monoclonal antibody drug being developed by UCB as a potential treatment for patients with tauopathies such as progressive supranuclear palsy (PSP) and Alzheimer’s Disease.
UCB will provide an exclusive, world-wide license to Roche and Genentech to develop and commercialize UCB0107 in AD. In return, UCB will receive an initial upfront payment of US $120 million. UCB will fund and perform a proof-of-concept study in AD and, upon availability of the results of that study, Genentech has the right to progress with the development or return full rights back to UCB. After Genentech’s decision to proceed with further clinical development, UCB will be eligible to receive further potential cost reimbursement, development and sales milestone payments as well as royalties with a total potential consideration approaching US $2 billion upon receipt of certain regulatory approvals and satisfying certain clinical and sales milestones.
<sup>
</sup> -
0 Replies
Sorry, there were no replies found.
Log in to reply.